Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H.

Clin Cancer Res. 2012 Aug 15;18(16):4449-57. doi: 10.1158/1078-0432.CCR-11-3351. Epub 2012 Jun 1.

2.

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.

Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

PMID:
24380695
3.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

4.

Zeroing in on ROS1 rearrangements in non-small cell lung cancer.

Stumpfova M, Jänne PA.

Clin Cancer Res. 2012 Aug 15;18(16):4222-4. doi: 10.1158/1078-0432.CCR-12-1812. Epub 2012 Aug 2.

5.

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.

Rogers TM, Russell PA, Wright G, Wainer Z, Pang JM, Henricksen LA, Singh S, Stanislaw S, Grille J, Roberts E, Solomon B, Fox SB.

J Thorac Oncol. 2015 Apr;10(4):611-8. doi: 10.1097/JTO.0000000000000465.

6.

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.

Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H.

Am J Surg Pathol. 2013 Apr;37(4):554-62. doi: 10.1097/PAS.0b013e3182758fe6.

PMID:
23426121
7.

[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].

Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.

Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):639-43. Chinese.

PMID:
26705279
9.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

10.

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.

Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, Wei P, Diao XL, Li X, Cao Q, Tian XX.

PLoS One. 2013 May 31;8(5):e64821. doi: 10.1371/journal.pone.0064821. Print 2013.

11.

Identification of ROS1 rearrangement in gastric adenocarcinoma.

Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM.

Cancer. 2013 May 1;119(9):1627-35. doi: 10.1002/cncr.27967. Epub 2013 Feb 7.

12.

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M.

Lung Cancer. 2015 Feb;87(2):122-9. doi: 10.1016/j.lungcan.2014.11.018. Epub 2014 Dec 6.

PMID:
25534130
13.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

PMID:
23788756
14.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M.

Mol Cancer Res. 2014 Jan;12(1):111-8. doi: 10.1158/1541-7786.MCR-13-0479-T. Epub 2013 Dec 2.

15.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

16.

Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.

Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, Asaka R, Okumura S, Nakagawa K, Mano H, Ishikawa Y.

Clin Cancer Res. 2011 May 15;17(10):3341-8. doi: 10.1158/1078-0432.CCR-11-0063. Epub 2011 Mar 23.

17.

Mouse model for ROS1-rearranged lung cancer.

Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T.

PLoS One. 2013;8(2):e56010. doi: 10.1371/journal.pone.0056010. Epub 2013 Feb 13.

18.

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS.

Lung Cancer. 2012 Aug;77(2):288-92. doi: 10.1016/j.lungcan.2012.03.004. Epub 2012 Mar 31.

PMID:
22465695
19.

Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.

Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, Liu HP, Chu Y, Chiu YT, Wu TH, Chou LH, Chen YR, Huang SF.

PLoS One. 2013 Aug 7;8(8):e70839. doi: 10.1371/journal.pone.0070839. eCollection 2013.

20.

ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.

Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, Kim SW, Choi CM, Park SI, Kim DK, Kim YH, Jang SJ.

Ann Surg Oncol. 2013 Jan;20(1):200-8. doi: 10.1245/s10434-012-2553-6. Epub 2012 Aug 23.

PMID:
22915320

Supplemental Content

Support Center